Compare Stocks → Your $200 account credit is about to expire (From MarketBeat) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADRONASDAQ:CYADNASDAQ:GEMPOTCMKTS:HBPCFNASDAQ:OASM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADROAduro Biotech$10.93$4.51▼$20.20$236.61M0.4162,237 shs171,500 shsCYADCelyad Oncology$0.60$0.67$0.46▼$3.07$15.91MN/AN/A3,009 shsGEMPGemphire Therapeutics$4.34+0.9%$4.97$0.24▼$1.49$64.54M2.82127,174 shs21,612 shsHBPCFHelix BioPharma$0.14$0.14$0.14▼$0.15$29.84M-0.11,544 shsN/AOASMOasmia Pharmaceutical AB (publ)$0.02$1.46$0.94▼$5.70$1.50M0.9698,414 shsN/AThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADROAduro Biotech0.00%0.00%0.00%0.00%0.00%CYADCelyad Oncology0.00%0.00%0.00%0.00%-33.05%GEMPGemphire Therapeutics+0.93%-1.14%-22.36%+17.41%+494.28%HBPCFHelix BioPharma0.00%-6.96%-5.03%-5.03%-5.68%OASMOasmia Pharmaceutical AB (publ)0.00%0.00%0.00%0.00%-60.00%Crypto Market Preps For Trillions Worth of Inflows! (Ad)Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online EventMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADROAduro BiotechN/AN/AN/AN/AN/AN/AN/AN/ACYADCelyad OncologyN/AN/AN/AN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADROAduro BiotechN/AN/AN/AN/ACYADCelyad OncologyN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AHBPCFHelix BioPharmaN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADROAduro Biotech$17.26M0.00N/AN/A$4.07 per share0.00CYADCelyad OncologyN/AN/AN/AN/A$0.20 per shareN/AGEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/AHBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)$220K6.82N/AN/A$0.63 per share0.03Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADROAduro Biotech-$82.37M-$5.15N/AN/AN/A-230.92%-101.73%-22.35%N/ACYADCelyad Oncology-$43.13MN/A0.00∞N/AN/AN/AN/AN/AGEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/AHBPCFHelix BioPharma-$4.69M-$0.04N/A∞N/AN/A-817.64%-308.71%6/12/2024 (Estimated)OASMOasmia Pharmaceutical AB (publ)-$18.95MN/A0.00∞N/A-8,633.64%-43.94%-28.92%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADROAduro BiotechN/AN/AN/AN/AN/ACYADCelyad OncologyN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AHBPCFHelix BioPharmaN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADROAduro BiotechN/A8.918.91CYADCelyad Oncology0.341.26N/AGEMPGemphire TherapeuticsN/A0.670.67HBPCFHelix BioPharmaN/A1.461.46OASMOasmia Pharmaceutical AB (publ)N/A0.800.73OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADROAduro Biotech49.93%CYADCelyad OncologyN/AGEMPGemphire Therapeutics17.53%HBPCFHelix BioPharmaN/AOASMOasmia Pharmaceutical AB (publ)0.11%Insider OwnershipCompanyInsider OwnershipADROAduro Biotech5.90%CYADCelyad Oncology0.94%GEMPGemphire Therapeutics22.70%HBPCFHelix BioPharma7.60%OASMOasmia Pharmaceutical AB (publ)N/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADROAduro Biotech15216.21 millionN/AOptionableCYADCelyad Oncology9526.52 million26.28 millionNot OptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableHBPCFHelix BioPharma9216.67 million200.21 millionNot OptionableOASMOasmia Pharmaceutical AB (publ)5774.97 millionN/ANot OptionableADRO, GEMP, CYAD, HBPCF, and OASM HeadlinesSourceHeadlineLipigon Pharmaceuticals AB LPGOmorningstar.com - March 23 at 12:53 AMLSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call Transcriptgurufocus.com - March 6 at 9:00 AMOasmia Pharmaceutical AB (publ) - Special Call Transcriptgurufocus.com - March 6 at 9:00 AMResurs Holding AB (publ) (RESURS.ST)finance.yahoo.com - February 8 at 12:32 AMQuiaPEG Pharmaceuticals Holding AB QUIAmorningstar.com - January 6 at 5:30 PMNewbury Pharmaceuticals AB (NEWBRY)investing.com - November 29 at 2:08 AMDentsu Creative bags mandate for Torrent Pharmaceuticals’ Shelcal & Unienzymebestmediainfo.com - September 26 at 1:06 AMLipigon Pharmaceuticals AB (LPGO)investing.com - September 14 at 9:09 AMSpeqta publ AB (SPEQT)investing.com - August 25 at 9:50 PMPRXXF Paradox Interactive AB (publ)seekingalpha.com - August 25 at 9:29 AMNotice of annual general meeting in Alzinova AB (publ)privataaffarer.se - April 25 at 8:37 AMReport from Annual General Meeting 2023 of PowerCell Sweden AB (publ)privataaffarer.se - April 21 at 8:26 PMNotice of Annual General Meeting 2023 in Enzymatica AB (publ) (2)europapress.es - April 2 at 9:53 AMOXE Marine AB (publ) Non-GAAP EPS of -SEK0.43, revenue of SEK32.2Mseekingalpha.com - February 26 at 11:56 PMUS regulators clear way for more monkeypox vaccine shipmentsstarherald.com - July 14 at 11:12 AMPRELIMINARY RESULT OF OASMIA’S RIGHTS ISSUE (MFN)avanza.se - March 24 at 6:47 AMOasmia expands R&D ability with planned laboratory upgradeprivataaffarer.se - March 17 at 8:40 AMOrexo appoints Fredrik Järrsten as new CFOstockhouse.com - March 11 at 3:47 AMNotice of extra general meeting in Terranet ABfinanznachrichten.de - November 29 at 10:24 AMPet Cancer Therapeutics Market – Know-How Industry to Experience Positive Growth | robust CAGR of 7.7% over the forecast period (2017 – 2025).medgadget.com - September 17 at 2:52 AMVeterinary Cancer Therapeutics Market Segmentation, Size Analysis, Key Players Forecast To 2027openpr.com - July 28 at 7:04 PMFancy Wood Industries PCL (FANCY)investing.com - July 22 at 7:07 PMCompany DescriptionsAduro BiotechNASDAQ:ADROChinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.Celyad OncologyNASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Gemphire TherapeuticsNASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.Helix BioPharmaOTCMKTS:HBPCFHelix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.Oasmia Pharmaceutical AB (publ)NASDAQ:OASMOasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.